All < Article List - KBR

주요서비스 바로가기 본문 바로가기 매체정보 바로가기 로그인 바로가기 기사검색 바로가기 전체서비스 바로가기

상단영역

UPDATE : 2024-04-18 16:11 (Thurs)

Home Log in Join

기사검색

본문영역

All articles 목록 ( 총 : 4,111 )

기사목록 보기 형태

제목형 요약형 포토형

1
2
3
4
5
6
7
8
9
10
다음

Recent News

HLB opens new office in Boston's Cambridge Innovation Center to bolster international market entry

Hanmi Pharm's novel drug receives INN name 'efpegerglucagon' for treating congenital hyperinsulinemia

SK biopharmaceuticals inks $58 million deal to transfer non-narcotic painkiller tech to Chinese partner

Handok and Swedish Orphan Biovitrum launch joint venture in Korea

GC Cell’s US affiliate initiates 1st patient dosing for lupus nephritis study

Photo News

HLB opens new office in Boston's Cambridge Innovation Center to bolster international market entry

Hanmi Pharm's novel drug receives INN name 'efpegerglucagon' for treating congenital hyperinsulinemia

SK biopharmaceuticals inks $58 million deal to transfer non-narcotic painkiller tech to Chinese partner

Handok and Swedish Orphan Biovitrum launch joint venture in Korea

Most Viewed

1 Watson & Company's wearable boosted athlete performance in 2022 Asian Games: CEO

2 Why are there radiotherapy limits for neuroendocrine tumors if there aren't any for thyroid cancer?

3 Celltrion partners with the Crohn's & Colitis Foundation to enhance IBD awareness in US

4 ‘Aggressive interferon treatment needed to reach MRD in myeloproliferative neoplasms’

5 [Photo News] UK Health Security Agency Chief Executive visits Seegene headquarters in Seoul

6 Samsung Bioepis secures 1st approval in Korea for Stelara biosimilar

7 AbbVie Korea’s psoriasis drug Skyrizi approved for pustular psoriasis on hands and feet

8 GE HealthCare Korea, LG Electronics, and Microsoft Korea collaborate to pioneer smart hospital innovation

하단영역

Latest: HLB opens new office in Boston's Cambridge Innovation Center to bolster international market entry

Hanmi Pharm's novel drug receives INN name 'efpegerglucagon' for treating congenital hyperinsulinemia

SK biopharmaceuticals inks $58 million deal to transfer non-narcotic painkiller tech to Chinese partner

Handok and Swedish Orphan Biovitrum launch joint venture in Korea

GC Cell’s US affiliate initiates 1st patient dosing for lupus nephritis study

Keytruda’s coverage expansion effectively ‘shelved’

Controversy erupts over alleged government hurdles for J-1 visas for Korean trainee doctors heading to US hospitals

Celltrion launches Remsima SC in Denmark

Coreline Soft begins non-reimbursed billing for AVIEW NeuroCAD brain CT analysis solution

'Bowel cleanser pill Orafang is safe for people over 70’

Important: Yonsei Cancer Hospital tops 500 robotic breast surgeries – a world record

Gangnam Severance Hospital makes breakthrough in early-onset Alzheimer's diagnosis

Daewoong submits NDA for diabetes treatment in Saudi Arabia

Crystal Genomics restarts as CG Invites

Kakao Healthcare workshop to explore limits of medical AI-DTx

CHA Vaccine Institute, Pharos iBio to co-develop AI-based immunotherapies

Compassion across borders: immigrant triplets born in KUAH

Boryung Consumer Healthcare launches 'Coenzyme Q10 Max'

‘Patients with pain conditions vulnerable to depression and higher mortality’

하단메뉴

About KBR Tip off Advertising Site Feedback Privacy Policy Adolescent Protection Policy E-mail address privacy

매체정보

The Korean Doctors’ Weekly Co., Ltd
76-1, Dongmak-ro, Mapo-gu, Seoul, Korea
Tel : 82-2-2646-0852
Fax : 82-2-703-3916
Title : KBR
Online newspaper registration number : Seoul 아 04285
Date of registration : December 19, 2016
Publishing date : February 22, 2017
CEO & Publisher : Yang Kyung-cheol
Managing Editor : Kim Yoon-mi
Juvenile Protection Manager: Lim Woong
Copyright © KBR. All rights reserved.

전체메뉴

All
Hospital
Pharma
Bio
- All
- Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Opinion
Congratulatory Remarks
Sponsored